A bispecific antibody trial for POEMS syndrome
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a new drug, BCMA/CD3 bispecific antibody, for people with POEMS syndrome. The drug helps the immune system attack abnormal plasma cells that cause the disease. It may offer a new treatment option for those who haven't had prior anti-plasma cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with POEMS syndrome (based on the 2025 Chinese Expert Consensus).
- You have not had any prior treatment that targets plasma cells, such as certain chemotherapies, immunomodulators, or CAR-T therapy (except for steroids, bisphosphonates, or autoimmune neuropathy drugs).
- You are physically able to handle daily activities (ECOG score 0-2).
- You do not have a known allergy to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy called CAR-T cells (genetically engineered immune cells) to treat POEMS syndrome that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment can help reduce symptoms and control the disease.
This trial tests a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people newly diagnosed with POEMS syndrome. It aims to see how well this treatment helps control the disease and its symptoms.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests a new combination of radiation therapy and a bispecific antibody (a drug that helps your immune system attack cancer cells) for people with a single bone plasmacytoma that has only a small number of abnormal cells in the bone marrow. It aims to see if this approach can control the disease better than radiation alone.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
Hear when a new POEMS Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.